{"name":"Mabwell (Shanghai) Bioscience Co., Ltd.","slug":"mabwell-shanghai-bioscience-co-ltd","ticker":"","exchange":"","domain":"mabwellshanghai.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"9MW2821","genericName":"9MW2821","slug":"9mw2821","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"9MW0813","genericName":"9MW0813","slug":"9mw0813","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"MW031","genericName":"MW031","slug":"mw031","indication":"Oncology indication (specific indication not publicly disclosed)","status":"phase_3"},{"name":"6MW3211","genericName":"6MW3211","slug":"6mw3211","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"9MW0311","genericName":"9MW0311","slug":"9mw0311","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"MW032","genericName":"MW032","slug":"mw032","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"7MW3711","genericName":"7MW3711","slug":"7mw3711","indication":"Other","status":"phase_1"},{"name":"9MW3011","genericName":"9MW3011","slug":"9mw3011","indication":"Other","status":"phase_1"},{"name":"7MW4911","genericName":"7MW4911","slug":"7mw4911","indication":"Other","status":"phase_1"},{"name":"9MW2921","genericName":"9MW2921","slug":"9mw2921","indication":"Other","status":"phase_1"},{"name":"9MW3811 injection","genericName":"9MW3811 injection","slug":"9mw3811-injection","indication":"Other","status":"phase_1"},{"name":"Other anti-cancer therapy","genericName":"Other anti-cancer therapy","slug":"other-anti-cancer-therapy","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"9MW2821","genericName":"9MW2821","slug":"9mw2821","phase":"phase_3","mechanism":"9MW2821 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"7MW3711","genericName":"7MW3711","slug":"7mw3711","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"9MW0813","genericName":"9MW0813","slug":"9mw0813","phase":"phase_3","mechanism":"9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"9MW3011","genericName":"9MW3011","slug":"9mw3011","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MW031","genericName":"MW031","slug":"mw031","phase":"phase_3","mechanism":"MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","indications":["Oncology indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"6MW3211","genericName":"6MW3211","slug":"6mw3211","phase":"phase_2","mechanism":"6MW3211 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"7MW4911","genericName":"7MW4911","slug":"7mw4911","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"9MW0311","genericName":"9MW0311","slug":"9mw0311","phase":"phase_3","mechanism":"9MW0311 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in phase 3)"],"catalyst":""},{"name":"9MW2921","genericName":"9MW2921","slug":"9mw2921","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"9MW3811 injection","genericName":"9MW3811 injection","slug":"9mw3811-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MW032","genericName":"MW032","slug":"mw032","phase":"phase_3","mechanism":"MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"Other anti-cancer therapy","genericName":"Other anti-cancer therapy","slug":"other-anti-cancer-therapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOWmdoSVZTdVhrc3VVWXlRWHdpT2l0Y3ZYSDBld0V5VlEwX1lEenNkNlBBMEI0X19WVVYxdGFuOWY3VzlLek5zbXBmVGVZMFFHamp5bFB0dmctLWs2RTRUQVM3eXFlLURMMW1kcUdvUllvUDVqRjJQR3ppRzI0SXRsZExxSGdiSFNaeGJpOGpqXzIwSEFUQ0dxdko5RFBUcWJUdHNzaWFiM2FaQ2lGdlBrVTV2V2RVaXgwRDNuX01ZdmFaQ05PNDZqdjRrT2hYaWxyZFk4d1FNUFdkQTlUYUZEU2sxaGh5ZkQxeTlTQ1dsQm1HQUhnX2JHTWE2Yw?oc=5","date":"2026-03-05","type":"trial","source":"Barchart.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0IyRmpWZzhoSnhlMVFEdVdtRzM2TjRtN0FfSXp5YjBSMHJVcGZwNlJxR09OODhWQWhIM3NRcV9pdEczQUhiaEs1aXpXYVlRWFlWb1k5QVVfd0t5bmQxRmVGblpDZVM4SmRtN2taaExmRU9KN3BmLU95bVRRM1V4aWtYaEZQVGpZNzRsOEVrSTdVc2FiVTFDcDJhb19DczA5M2IzM0FR?oc=5","date":"2025-12-09","type":"pipeline","source":"BioWorld News","summary":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025 - BioWorld News","headline":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOVjJkdnVoRmNpYm1naUwxTzhpQTRLaWlLMUZSZnJPSkNyaUNVOTBrQzc3dUFjMWtxamVoNHNOMlYzVE5aUU56SDd5eExUNEZuaFdENTBsN0NhdVotUE84OHpRUFZENXF5LWVsN1dKMEZjSV9DS2NOZS1GdWswMTk5NzQ5aktzTU15RWlPa0pva2pLWEJ5WXc?oc=5","date":"2025-09-17","type":"pipeline","source":"Contract Pharma","summary":"Mabwell Bioscience, Aditum Bio Form Kalexo Bio - Contract Pharma","headline":"Mabwell Bioscience, Aditum Bio Form Kalexo Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPMlJzdE1mR2hBOUhxMFZ1RUJBcEhCUGZ3Smthd2hkRFZ0cl9UWl95N3RQQXhxemRHYlBGb2RpbHlIWm9PcWFCeGZkaTRIeHA1dlp5V1RrN3U3LUxMek1pYmhMalhuVG5tZUhXdzRXYWJLNktfYVY0UWJUWGRha043MjQxSEtwVVdxMFlzX25qTDJWSHNFeXNKTVZKeWQxZnFoQ0dj?oc=5","date":"2025-07-17","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQVGhLNGF1QzFjZ2Y2dG8zLXBVSVZoaENDTWFFeW9nZ0otZmRYNHZqWlZ4U1FjNm5BazBURzlwc1IyWmJEcHoxcjRYdHV6V1pENDVDUXc2WENJV3FYNHVibmhpZEJGTkNaOWRpbDNVSmdRMzBXSEl6MmI3R0dfQ0VORnptSDdHSTVfMWpuM25hc3JZQTVuNnhidlRaZFpTZmE5U2RoWE5XMllIQlk1Z1RhVkJHV3B4a1ZGUWxmZGxhN2hpR2RNQkRsZ2JWZjNQTHBKLU1hMy00a0NndHlOb215OE9NZ1U5WklzWnVaZXJZVTNDZWM2Z0hYZDhWdThaUVp6ZG9CbldRSkZDTXc2R3ZnRFd3TDlkZ3ZPaDVtLXJxWlFySG1ZUjA4d2dRVjNOdlVLU1V1Vg?oc=5","date":"2024-09-24","type":"trial","source":"globenewswire.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With - globenewswire.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQT2JHOS10My10X3NzR1dxOTdJVm5sajdQSlFXYWJ4T1l4SXphWnZVVDZZejg3bVkzTFBvaFJUa2F6QmJqT1c5MHRnXzdlTVp3NjMtNXBNYVNaZ1ZZNkRwRTB2bEZkYV9XWXBWeTljZ1VkRG5VOVZreTNFaUdzSndxTXJ0MXdSOVlXSHplZHlZVXlqTzFIZ3ZZTjUxUElQY3Q2NkRiWHJweWpLeXNRa0pTYXNaSk5UY2JpdFEwdXZrQU0wbDNoQUt2cGN3aEdkYThZNTdTRXdB?oc=5","date":"2021-08-27","type":"patent","source":"BioSpectrum Asia","summary":"Chinese Bio-pharma firm to authorize recombinant arthritis biosimilar drug in Singapore - BioSpectrum Asia","headline":"Chinese Bio-pharma firm to authorize recombinant arthritis biosimilar drug in Singapore","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":5,"phase_1":6,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}